Table of Contents
Chemotherapy Research and Practice
Volume 2011, Article ID 963159, 10 pages
http://dx.doi.org/10.1155/2011/963159
Review Article

Nedaplatin: A Radiosensitizing Agent for Patients with Cervical Cancer

Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan

Received 17 June 2010; Accepted 27 August 2010

Academic Editor: Athanassios Tsakris

Copyright © 2011 Seiji Mabuchi and Tadashi Kimura. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. Kanzawa, Y. Matsushima, H. Nakano, K. Nakagawa, H. Takahashi, Y. Sasaki, and N. Saijo, “Antitumor activity of a new platinum compound (glycolate o,o') diammineplatinum (II) (254-S), against non-small cell lung carcinoma grown in a human tumor clonogenic assay system,” Anticancer Research, vol. 8, no. 3, pp. 323–327, 1988. View at Google Scholar · View at Scopus
  2. B. J. Monk, D. S. Alberts, R. A. Burger, P. T. Fanta, A. V. Hallum III, K. D. Hatch, and S. E. Salmon, “In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human cervical cancers,” Gynecologic Oncology, vol. 71, no. 2, pp. 308–312, 1998. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. Y. Sasaki, T. Shinkai, K. Eguchi, T. Tamura, Y. Ohe, T. Ohmori, and N. Saijo, “Prediction of the antitumor activity of new platinum analogs based on their ex vivo pharmacodynamics as determined by bioassay,” Cancer Chemotherapy and Pharmacology, vol. 27, no. 4, pp. 263–270, 1991. View at Google Scholar · View at Scopus
  4. T. Uehara, H. Watanabe, and H. Watanabe, “Nephrotoxicity of a novel antineoplastic platinum complex, nedaplatin: a comparative study with cisplatin in rats,” Archives of Toxicology, vol. 79, no. 8, pp. 451–460, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. Y. Kawai, S. Taniuchi, S. Okahara, M. Nakamura, and M. Gemba, “Relationship between cisplatin or nedaplatin-induced nephrotoxicity and renal accumulation,” Biological and Pharmaceutical Bulletin, vol. 28, no. 8, pp. 1385–1388, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Fukuda, T. Shinkai, and T. Shinkai, “Phase II study of (glycolate-O,O') diammineplatinum(II), a novel platinum complex, in the treatment of non-small-cell lung cancer,” Cancer Chemotherapy and Pharmacology, vol. 26, no. 6, pp. 393–396, 1990. View at Google Scholar · View at Scopus
  7. Y. Inuyama, H. Miyake, M. Horiuchi, K. Hayasaki, S. Komiyama, and K. Ota, “An early phase II clinical study of cis-diammine glycolato platinum, 254-S, for head and neck cancers,” Japanese Journal of Cancer and Chemotherapy, vol. 19, no. 6, pp. 863–869, 1992. View at Google Scholar · View at Scopus
  8. T. Kato, H. Nishimura, M. Yakushiji et al., “Phase II study of 254-S (cis-diammine glycolato platinum) for gynecological cancer,” Gan To Kagaku Ryoho, vol. 19, pp. 695–701, 1992. View at Google Scholar
  9. N. Yamamoto, T. Tamura, and T. Tamura, “A dose-finding and pharmacokinetic study of nedaplatin in elderly patients with advanced non-small cell lung cancer,” Cancer Chemotherapy and Pharmacology, vol. 65, no. 1, pp. 79–88, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. S. Mabuchi, K. Morishige, M. Fujita, T. Tsutsui, M. Sakata, T. Enomoto, and T. Kimura, “The activity of carboplatin and paclitaxel for recurrent cervical cancer after definitive radiotherapy,” Gynecologic Oncology, vol. 113, no. 2, pp. 200–204, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. Y. Nakamura, M. Hasegawa, K. Hayakawa et al., “Induction of p53-dependent apoptosis in vivo by nedaplatin and ionizing radiation,” Oncology Reports, vol. 7, no. 2, pp. 261–265, 2000. View at Google Scholar
  12. T. Tanaka, K. Yukawa, and N. Umesaki, “Radiation reduces carboplatin sensitivity and enhances nedaplatin sensitivity in cervical squamous cell carcinoma in vitro,” European Journal of Gynaecological Oncology, vol. 28, no. 5, pp. 352–355, 2007. View at Google Scholar · View at Scopus
  13. Y. Sato, T. Takayama, and T. Takayama, “A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with esophageal cancer,” Cancer Chemotherapy and Pharmacology, vol. 58, no. 5, pp. 570–576, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. Y. Onishi, T. Nakamura, M. Hatae, S. Adachi, and T. Ogasawara, “Phase I study of weekly and radiation therapy for advanced cervical cancer,” Proceedings of the American Society of Clinical Oncology, vol. 21, article 111b, 2002. View at Google Scholar
  15. K. Yoshinaga, H. Niikura, and H. Niikura, “Phase I trial of concurrent chemoradiation with weekly nedaplatin in patients with squamous cell carcinoma of the uterine cervix,” Gynecologic Oncology, vol. 104, no. 1, pp. 36–40, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. Y. Yokoyama, T. Takano, and T. Takano, “A phase II multicenter trial of concurrent chemoradiotherapy with weekly nedaplatin in advanced uterine cervical carcinoma: Tohoku gynecologic cancer unit study,” Oncology Reports, vol. 19, no. 6, pp. 1551–1556, 2008. View at Google Scholar · View at Scopus
  17. Y. Niibe, S. Tsunoda, and S. Tsunoda, “Phase II study of radiation therapy combined with weekly nedaplatin in locally advanced uterine cervical carcinoma (LAUCC): Kitasato Gynecologic Radiation Oncology Group (KGROG 0501)—initial analysis,” European Journal of Gynaecological Oncology, vol. 29, no. 3, pp. 222–224, 2008. View at Google Scholar · View at Scopus
  18. S. Mabuchi, K.-I. Morishige, and K.-I. Morishige, “Postoperative concurrent nedaplatin-based chemoradiotherapy improves survival in early-stage cervical cancer patients with adverse risk factors,” Gynecologic Oncology, vol. 115, no. 3, pp. 482–487, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. J. Kodama, M. Takemoto, N. Seki, K. Nakamura, A. Hongo, S. Kanazawa, and Y. Hiramatsu, “Phase I study of weekly nedaplatin and concurrent pelvic radiotherapy as adjuvant therapy after radical surgery for cervical cancer,” International Journal of Gynecological Cancer, vol. 18, no. 5, pp. 1037–1041, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. S. Mabuchi, H. Ugaki, and H. Ugaki, “Concurrent weekly nedaplatin, external beam radiotherapy and high-dose-rate brachytherapy in patients with FIGO stage IIIb cervical cancer: a comparison with a cohort treated by radiotherapy alone,” Gynecologic and Obstetric Investigation, vol. 69, no. 4, pp. 224–232, 2010. View at Publisher · View at Google Scholar · View at PubMed
  21. Y. Kobayashi, T. Ohara, and T. Ohara, “Concurrent chemoradiotherapy with nedaplatin after radical hysterectomy in patients with stage IB and II cervical cancer,” Journal of Obstetrics and Gynaecology Research, vol. 35, no. 3, pp. 490–494, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. T. Teshima, T. Inoue, and T. Inoue, “High-dose rate and low-dose rate intracavitary therapy for carcinoma of the uterine cervix: final results of Osaka University Hospital,” Cancer, vol. 72, no. 8, pp. 2409–2414, 1993. View at Google Scholar
  23. M. Hareyama, K.-I. Sakata, A. Oouchi, H. Nagakura, M. Shido, M. Someya, and K. Koito, “High-dose-rate versus low-dose-rate intracavitary therapy for carcinoma of the uterine cervix: a randomized trial,” Cancer, vol. 94, no. 1, pp. 117–124, 2002. View at Publisher · View at Google Scholar · View at PubMed
  24. P. Lertsanguansinchai, C. Lertbutsayanukul, and C. Lertbutsayanukul, “Phase III randomized trial comparing LDR and HDR brachytherapy in treatment of cervical carcinoma,” International Journal of Radiation Oncology Biology Physics, vol. 59, no. 5, pp. 1424–1431, 2004. View at Publisher · View at Google Scholar · View at PubMed
  25. M. Morris, P. J. Eifel, and P. J. Eifel, “Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer,” The New England Journal of Medicine, vol. 340, no. 15, pp. 1137–1143, 1999. View at Publisher · View at Google Scholar · View at PubMed
  26. P. G. Rose, B. N. Bundy, and B. N. Bundy, “Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer,” The New England Journal of Medicine, vol. 340, no. 15, pp. 1144–1153, 1999. View at Publisher · View at Google Scholar · View at PubMed
  27. T. Toita, H. Moromizato, K. Ogawa, Y. Kakinohana, T. Maehama, K. Kanazawa, and S. Murayama, “Concurrent chemoradiotherapy using high-dose-rate intracavitary brachytherapy for uterine cervical cancer,” Gynecologic Oncology, vol. 96, no. 3, pp. 665–670, 2005. View at Publisher · View at Google Scholar · View at PubMed
  28. Y.-L. Chung, J. J.-M. Jian, and J. J.-M. Jian, “Extended-field radiotherapy and high-dose-rate brachytherapy with concurrent and adjuvant cisplatin-based chemotherapy for locally advanced cervical cancer: a phase I/II study,” Gynecologic Oncology, vol. 97, no. 1, pp. 126–135, 2005. View at Publisher · View at Google Scholar · View at PubMed
  29. S.-W. Chen, J.-A. Liang, and J.-A. Liang, “Concurrent weekly cisplatin plus external beam radiotherapy and high-dose rate brachytherapy for advanced cervical cancer: a control cohort comparison with radiation alone on treatment outcome and complications,” International Journal of Radiation Oncology Biology Physics, vol. 66, no. 5, pp. 1370–1377, 2006. View at Publisher · View at Google Scholar · View at PubMed
  30. R. Pötter, J. Dimopoulos, and J. Dimopoulos, “3D conformal HDR-brachy- and external beam therapy plus simultaneous cisplatin for high-risk cervical cancer: clinical experience with 3 year follow-up,” Radiotherapy and Oncology, vol. 79, no. 1, pp. 80–86, 2006. View at Publisher · View at Google Scholar · View at PubMed
  31. A. P. Novetsky, M. H. Einstein, and M. H. Einstein, “Efficacy and toxicity of concomitant cisplatin with external beam pelvic radiotherapy and two high-dose-rate brachytherapy insertions for the treatment of locally advanced cervical cancer,” Gynecologic Oncology, vol. 105, no. 3, pp. 635–640, 2007. View at Publisher · View at Google Scholar · View at PubMed
  32. P. G. Rose, “Chemoradiotherapy: the new standard care for invasive cervical cancer,” Drugs, vol. 60, no. 6, pp. 1239–1244, 2000. View at Google Scholar
  33. “National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology, Cervical Cancer v.1,” 2010, http://www.nccn.org/professionals/physician_gls/PDF/cervical.pdf.
  34. Y. Watanabe, H. Nakai, M. Shimaoka, T. Tobiume, I. Tsuji, and H. Hoshiai, “Feasibility of concurrent cisplatin use during primary and adjuvant chemoradiation therapy: a phase I study in Japanese patients with cancer of the uterine cervix,” International Journal of Clinical Oncology, vol. 11, no. 4, pp. 309–313, 2006. View at Publisher · View at Google Scholar · View at PubMed
  35. F. Landoni, A. Maneo, and A. Maneo, “Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer,” The Lancet, vol. 350, no. 9077, pp. 535–540, 1997. View at Publisher · View at Google Scholar
  36. R. A. K. Samlal, J. van der Velden, M. S. Schilthuis, D. González González, F. J. W. Ten Kate, A. A. M. Hart, and F. B. Lammes, “Identification of high-risk groups among node-positive patients with stage IB and IIA cervical carcinoma,” Gynecologic Oncology, vol. 64, no. 3, pp. 463–467, 1997. View at Publisher · View at Google Scholar
  37. G. Delgado, B. Bundy, R. Zaino, B.-U. Sevin, W. T. Creasman, and F. Major, “Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a gynecologic oncology group study,” Gynecologic Oncology, vol. 38, no. 3, pp. 352–357, 1990. View at Publisher · View at Google Scholar
  38. A. F. Fuller Jr., N. Elliott, C. Kosloff, W. J. Hoskins, and J. L. Lewis Jr., “Determinants of increased risk for recurrence in patients undergoing radical hysterectomy for Stage IB and IIA carcinoma of the cervix,” Gynecologic Oncology, vol. 33, no. 1, pp. 34–39, 1989. View at Google Scholar
  39. M. Rotman, A. Sedlis, M. R. Piedmonte, B. Bundy, S. S. Lentz, L. I. Muderspach, and R. J. Zaino, “A phase III randomized trial of postoperative pelvic irradiation in Stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study,” International Journal of Radiation Oncology Biology Physics, vol. 65, no. 1, pp. 169–176, 2006. View at Publisher · View at Google Scholar · View at PubMed
  40. A. Sedlis, B. N. Bundy, M. Z. Rotman, S. S. Lentz, L. I. Muderspach, and R. J. Zaino, “A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a gynecologic oncology group study,” Gynecologic Oncology, vol. 73, no. 2, pp. 177–183, 1999. View at Publisher · View at Google Scholar · View at PubMed
  41. W. A. Peters III, P. Y. Liu, and P. Y. Liu , “Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix,” Journal of Clinical Oncology, vol. 18, no. 8, pp. 1606–1613, 2000. View at Google Scholar
  42. J. L. Benedet, F. Odicino, and F. Odicino, “Carcinoma of the cervix uteri,” International Journal of Gynecology and Obstetrics, vol. 83, no. 1, pp. 41–78, 2003. View at Publisher · View at Google Scholar
  43. J. J. Kovalic, C. A. Perez, P. W. Grigsby, and M. A. Lockett, “The effect of volume of disease in patients with carcinoma of the uterine cervix,” International Journal of Radiation Oncology Biology Physics, vol. 21, no. 4, pp. 905–910, 1991. View at Google Scholar
  44. C. W. Whitney, W. Sause, and W. Sause, “Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group Study,” Journal of Clinical Oncology, vol. 17, no. 5, pp. 1339–1348, 1999. View at Google Scholar
  45. H. M. Keys, B. N. Bundy, and B. N. Bundy, “Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma,” The New England Journal of Medicine, vol. 340, no. 15, pp. 1154–1161, 1999. View at Publisher · View at Google Scholar · View at PubMed
  46. C. Vale, J. F. Tierney, and J. F. Tierney, “Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials,” Journal of Clinical Oncology, vol. 26, no. 35, pp. 5802–5812, 2008. View at Publisher · View at Google Scholar · View at PubMed
  47. S.-K. Lee and H. W. Jones III, “Prognostic significance of ureteral obstruction in primary cervical cancer,” International Journal of Gynecology and Obstetrics, vol. 44, no. 1, pp. 59–65, 1994. View at Publisher · View at Google Scholar
  48. National Cancer Institute Clinical Announcement, “Concurrent Chemoradiation for Cervical Cancer,” February 1999, http://www.cancer.gov/newscenter/cervicalcancer.
  49. J. A. Green, J. M. Kirwan, J. F. Tierney, P. Symonds, L. Fresco, M. Collingwood, and C. J. Williams, “Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis,” The Lancet, vol. 358, no. 9284, pp. 781–786, 2001. View at Publisher · View at Google Scholar · View at PubMed